Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease

Marine Drugs

Jiayao Feng¹  Yongjian Liu¹  Jiajia Chen¹  Zhengquan Su¹  Jiao Guo²  Qishi Che³  Hua Cao⁴  Yan Bai⁵  Jincan He⁵ 

[1] Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China;Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China;Guangzhou Rainhome Pharm & Tech Co., Ltd., Science City, Guangzhou 510663, China;School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China;School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China;

关键词: marine chitooligosaccharide;    nonalcoholic fatty liver disease;    intestinal flora;    LPS/TLR4/NF-κB inflammatory pathway;    short-chain fatty acid;   

DOI  :  10.3390/md20060383

来源: DOAJ

【 摘 要 】

In this study, C57BL/6 mice were given an HFHSD diet for 8 weeks to induce hepatic steatosis and then given COSM solution orally for 12 weeks. The study found that the HFHSD diet resulted in steatosis and insulin resistance in mice. The formation of NAFLD induced by HFHSD diet was related to the imbalance of intestinal flora. However, after COSM intervention, the abundance of beneficial bacteria increased significantly, while the abundance of harmful bacteria decreased significantly. The HFHSD diet also induced changes in intestinal bacterial metabolites, and the content of short-chain fatty acids in cecal contents after COSM intervention was significantly higher than that in the model group. In addition, COSM not only improved LPS levels and barrier dysfunction in the ileum and colon but upregulated protein levels of ZO-1, occludin, and claudin in the colon and downregulated the liver LPS/TLR4/NF-κB inflammatory pathway. We concluded that the treatment of marine chitooligosaccharide COSM could improve the intestinal microflora structure of the fatty liver and activate an inflammatory signaling pathway, thus alleviating the intrahepatic lipid accumulation induced by HFHSD.

【 授权许可】

Unknown